Cancer - Side effect drugs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cancer - Side effect drugs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who started this subject	5/18/2002 1:44:56 PM
From: John McCarthy	of 57

[2002]-[BNP7787]-[BioNumerik Pharmaceuticals, Inc.] BioNumerik Pharmaceuticals, Inc. PROFILE BioNumerik Pharmaceuticals crunches the numbers to develop drugs that fight cancer and the side effects associated with many therapies. The firm's "mechanism-based" approach relies heavily on computer models and simulations to identify promising drug candidates; it has access to supercomputer technology through an alliance with Cray Inc. The company's lead product candidate, BNP7787 (to prevent nerve and kidney damage caused by cancer treatments), has been granted fast-track development status from the FDA. Nearly all of the firm's revenue comes from a joint venture with an affiliate of leading Japanese drugmaker Takeda Chemical Industries. Founder and chairman Frederick Hausheer owns nearly a third of BioNumerik. thestandard.net

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next